Cjc-1295

CJC-1295 is a tetrasubtituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was innovated by ConjuChem, a Canadian biotechnology company.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug's marketing stalled when three of the trial's patients suffered a myocardial infarction.

References

*Falutz, J et al. "A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation." "AIDS." 2005 August 12;19(12):1279-87.

*Tiechman, SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." "J Clin Endocrinol Metab". 2006 March 91(3):799-805. Epub 2005 December 13.